Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area Devjit S Nayar Gastroenterology Associates of Central Jersey, Edison, NJ, USA Background: In order to mitigate potential issues with antibiotic resistance in the treatment of patients with Helicobacter pylori infection, the selection of a therapeutic regimen is optimized by being aware of local eradication rates as well as the patient’s medication history and previous diagnoses. Purpose: This study primarily aimed to calculate the eradication rate of H. pylori infection in the New York Metropolitan area when using clarithromycin-based triple therapy per the dosing instructions for Omeclamox®-Pak. A secondary objective was to determine risk factors for therapeutic failure. Patients and methods: A retrospective analysis was performed on 156 patients treated with clarithromycin-based triple therapy between 2011 and 2017 at a gastroenterology practice in Edison, New Jersey. Results: The cumulative eradication rate for the intent-to-treat population was 84%, while the per-protocol rate was 86%. No differences were seen in the rates of subgroups defined by demographics or medication history. Conclusion: Despite evidence and predictions from other sources in the last decade that clarithromycin-based treatments for H. pylori are becoming less effective, the results of this study support the use of clarithromycin-based triple therapy as a first-line treatment in the New York Metropolitan region. Keywords: H. pylori, dyspepsia, antibiotic resistance, bismuth quadruple therapy, Omeclamox